论文部分内容阅读
中国加入WTO之后，许多企业都将面临异常激烈的竞争，而其中医药企业之间的竞争尤其白热化。我国现在药品生产企业6300多家，但这些药厂有不少处于小、乱、劣的状况。其中有相当多数尚未通过GMP（药品生产质量管理规范）和GSP（药品经营质量管理规范）认证。更为严重的是，近年
After China’s accession to the WTO, many enterprises will face fierce competition, and the competition among the pharmaceutical companies will be intensified. At present, there are more than 6,300 pharmaceutical manufacturers in our country, but many of these pharmaceutical factories are in small, chaotic and inferior conditions. A considerable number of them have not yet passed the GMP (Good Manufacturing Practice) and GSP (Good Manufacturing Practices) certification. More serious is in recent years